| Zacks Company Profile for Fate Therapeutics, Inc. (FATE : NSDQ) |
|
|
| |
| • Company Description |
| Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.
Number of Employees: 551 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $5.70 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,155,282 shares |
| Shares Outstanding: 98.16 (millions) |
| Market Capitalization: $559.52 (millions) |
| Beta: 1.53 |
| 52 Week High: $43.12 |
| 52 Week Low: $4.02 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-6.40% |
-9.32% |
| 12 Week |
-48.18% |
-51.98% |
| Year To Date |
-43.51% |
-50.21% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
J. Scott Wolchko - President and Chief Executive Officer and Director
William H. Rastetter - Chairman of the Board and Director
John D. Mendlein - Vice Chairman of the Board and Director
Edward J. Dulac III - Chief Financial Officer
Shefali Agarwal - Director
|
|
Peer Information
Fate Therapeutics, Inc. (CORR.)
Fate Therapeutics, Inc. (RSPI)
Fate Therapeutics, Inc. (CGXP)
Fate Therapeutics, Inc. (BGEN)
Fate Therapeutics, Inc. (GTBP)
Fate Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 31189P102
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 05/03/23
|
|
Share - Related Items
Shares Outstanding: 98.16
Most Recent Split Date: (:1)
Beta: 1.53
Market Capitalization: $559.52 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.57 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.14 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 12.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 30.90% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 05/03/23 |
|
|
|
| |
